Ross Moat - 01 Apr 2024 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
CHIEF COMMERCIAL OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
01 Apr 2024
Transactions value $
-$17,336
Form type
4
Filing time
03 Apr 2024, 17:20:15 UTC
Previous filing
06 Sep 2023
Next filing
08 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise +1.61K +11.18% 16K 01 Apr 2024 Direct F1
transaction KNSA Class A Common Share Tax liability -$17.3K -880 -5.49% $19.70 15.2K 01 Apr 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Unit Options Exercise $0 -1.61K -25.01% $0.00 4.83K 01 Apr 2024 Class A Common Share 1.61K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, April 1, 2023.